Patents Assigned to INTRABIO LTD
  • Therapeutic agents for improved mobility and cognitive function and for treating neurodegenerative diseases and lysosomal storage disorders
    Patent number: 12458614
    Abstract: The present disclosure provides for treating neurodegenerative diseases and lysosomal storage disorders comprising administering leucine, or a pharmaceutically acceptable salt thereof for direct delivery in a subject in need thereof. The disclosure further provides for leucine, or a pharmaceutically acceptable salt thereof for direct delivery in a subject in need thereof, for example, in an elderly subject, to improve cognitive function, mobility, or cognitive function and mobility.
    Type: Grant
    Filed: October 18, 2018
    Date of Patent: November 4, 2025
    Assignee: Intrabio Ltd
    Inventor: Mallory Factor
  • Acetyl-leucine or a pharmaceutically acceptable salt thereof for improved mobility and cognitive function
    Patent number: 11998518
    Abstract: The present disclosure is directed to acetyl-leucine or a pharmaceutically acceptable salt thereof for use in improving cognitive function, mobility, or cognitive function and mobility in a subject, for example, in an elderly subject.
    Type: Grant
    Filed: December 22, 2020
    Date of Patent: June 4, 2024
    Assignee: INTRABIO LTD
    Inventors: Mallory Factor, Michael Strupp
  • BETAHISTINE, OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, AND A MONOAMINE OXIDASE INHIBITOR, FOR USE IN THE TREATMENT OR PREVENTION OF ONE OR MORE SYMPTOMS OF VERTIGO IN A SUBJECT
    Publication number: 20210085659
    Abstract: A first aspect of the invention relates to betahistine, or a pharmaceutically acceptable salt thereof, and a monoamine oxidase inhibitor, for use in the treatment or prevention of one or more symptoms of vertigo in a subject. A second aspect of the invention relates to a method of treating or preventing one or more symptoms of vertigo in a subject, said method comprising administering to the subject (i) betahistine, or a pharmaceutically acceptable salt thereof, and (ii) a monoamine oxidase inhibitor.
    Type: Application
    Filed: March 28, 2018
    Publication date: March 25, 2021
    Applicant: INTRABIO LTD
    Inventor: Michael STRUPP
  • THERAPEUTIC AGENTS FOR IMPROVED MOBILITY AND COGNITIVE FUNCTION AND FOR TREATING NEURODEGENERATIVE DISEASES AND LYSOSOMAL STORAGE DISORDERS
    Publication number: 20200338034
    Abstract: The present disclosure provides for treating neurodegenerative diseases and lysosomal storage disorders comprising administering leucine, or a pharmaceutically acceptable salt thereof for direct delivery in a subject in need thereof. The disclosure further provides for leucine, or a pharmaceutically acceptable salt thereof for direct delivery in a subject in need thereof, for example, in an elderly subject, to improve cognitive function, mobility, or cognitive function and mobility.
    Type: Application
    Filed: October 18, 2018
    Publication date: October 29, 2020
    Applicant: INTRABIO LTD
    Inventor: Mallory FACTOR